ELOX Eloxx Pharmaceuticals, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ELOX
—
—
Key stats
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.96% |
| WACC | 10.12% |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Return on Equity (TTM) | 62.7% |
| Book / Price | 105.5% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $15.74 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $14.00 |
| Bollinger Width / SMA20 | 235.6% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: AMGN, ARGX, BIIB, BNTX, EXEL, GILD, MRNA, RVMD
Blended Fair Value
$189.03
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 27.2× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.3× · 4 peers |
| Peer P/B | $189.03 | 100% | median 13.6× · 6 peers |
| Peer P/S | n/a | 0% | median 6.3× · 5 peers |
| Market Anchor (SMA50) | $15.74 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 7
- List Date
- 1998-12-11
- CIK
- 0001035354
- Next Earnings
- 2026-11-10
- Headquarters
- Arlington, MA
- Homepage
- https://www.eloxxpharma.com
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -10.88% | -31.63% | 60.31% | -6.04% | -- | 0.00% | 2.35% |
| Feb | 25.98% | -13.27% | -25.17% | 4.76% | 0.00% | 0.00% | -1.28% |
| Mar | -22.79% | 31.28% | -24.17% | 12.42% | 0.00% | 80700.00% | 13449.46% |
| Apr | -35.12% | -42.32% | 183.52% | -5.77% | 0.00% | 50.00% | 25.05% |
| May | -31.58% | -12.33% | -3.30% | -3.41% | 0.00% | 94.74% | 7.35% |
| Jun | 22.84% | -10.36% | -44.43% | -5.00% | 0.00% | 26.07% | -1.81% |
| Jul | -34.00% | 7.95% | 57.83% | -2.78% | 0.00% | 42.99% | 12.00% |
| Aug | 17.39% | 43.88% | -14.54% | 0.00% | 0.00% | -9.11% | 6.27% |
| Sep | 3.82% | -54.26% | -10.93% | 0.00% | 0.00% | 2.00% | -9.89% |
| Oct | -14.91% | -15.18% | -77.52% | 100.00% | 0.00% | -16.17%* | -3.96% |
| Nov | -48.35% | -8.42% | -1.72% | -50.00% | 0.00% | -- | -21.70% |
| Dec | -2.13% | -52.51% | 9.09% | 0.00% | 0.00% | -- | -9.11% |
| Total | -83.65% | -90.75% | -59.87% | -6.98% | 0.00% | 330567.07% | 55054.30% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $14.00
SMA 50: $15.74
SMA 200: $7.51
Current: $13.17
EMA 12: $13.40
EMA 26: $14.19
MACD: -0.7932 | Signal: -0.0083
BEARISH
ADX (14): 26.17
TREND
+DI: 11.81
−DI: 19.62
Momentum Oscillators
RSI (14): 42.58
NEUTRAL
Stoch %K: 24.88
Stoch %D: 24.50
Williams %R: -68.55
Volume & Volatility
BB Upper: $16.30
BB Lower: $11.69
NEUTRAL
OBV: 4,461,739
Vol SMA 20: 23,777
Vol ROC: 2.22%
ATR: $1.39
True Range: $0.55
HV 20: 76.2%
HV 30: 77.9%
HV 60: 92.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2023-05-30T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: BULLISH (confidence level: 7/10)
Key drivers:
- Technical momentum signals indicate a potential uptrend
- Recent news headlines highlight positive market trends and growth expectations for the industry
Primary risks:
- High volatility, which may lead to whipsaws or significant price swings
- Negative sentiment from some recent headlines and market expectations
Investment thesis:
ELOX has demonstrated technical momentum signals indicating a potential uptrend. This, combined with positive news sentiment and growth expectations in the industry, suggests a bullish case for the stock.
Recent news sentiment impact:
The positive news sentiment from the first two recent headlines has likely contributed to the upward price movement, as investors have become more optimistic about the company's prospects.
Technical Analysis
Trend direction: Short-term (1-4 weeks) - Uptrend
Support/Resistance levels:
- Lower Bollinger Band: $13.73
- Middle Bollinger Band: $17.40
- Upper Bollinger Band: $21.08
Momentum signals:
- MACD signal line crossover above zero: Bullish momentum
- RSI interpretation: Neutral (49.72)
- Stochastic %K and %D both below 50: Bearish momentum (not dominant)
Volume analysis:
- Volume SMA 20: 46627.60
- On-Balance Volume (OBV): 5555622.07
- Volume Rate of Change: 2.97%
News & Sentiment Analysis
Recent headlines summary:
The first two recent headlines highlight positive market trends and growth expectations for the industry, which may have contributed to the upward price movement.
Sentiment assessment: Positive
Catalyst identification:
- No imminent catalysts identified
Market narrative:
The news sentiment aligns with the technical signals, suggesting a potential uptrend. However, high volatility and negative sentiment from some recent headlines introduce risk factors that should be monitored.
Risk & Volatility Assessment
Beta interpretation:
- Beta: -1794.57 (vs SPY) - high volatility
Volatility regime:
- Current vs historical volatility levels: High volatility relative to historical norms
Options market signals:
- IV Rank: 0.0% (Low)
- Current IV: 0.0%
- Expected Move: $0.00 (None DTE), 7-DTE: $0.00
- Volume Flow: 0 calls vs 0 puts
- Open Interest: 0 calls vs 0 puts
Downside protection:
- Support levels and risk management considerations:
- Lower Bollinger Band: $13.73
- Middle Bollinger Band: $17.40
Market Context & Positioning
Sector performance:
- Relative strength vs sector/market: Strong relative strength in the biotech industry
Institutional activity:
- Volume patterns suggesting institutional interest: 5555622.07 OBV, indicating significant buying pressure
Correlation analysis:
- R-squared interpretation: High correlation with the biotech industry (0.9)
Relative valuation:
- Position within trading range: Bullish, as price has been trending upward and relative to its peers.
Key Levels & Action Items
Critical price levels:
- Support/resistance to monitor:
- Lower Bollinger Band: $13.73
- Middle Bollinger Band: $17.40
- Upper Bollinger Band: $21.08
Breakout/breakdown levels:
- Technical levels that could trigger significant moves:
- Above the upper Bollinger Band ($21.08)
- Below the lower Bollinger Band ($13.73)
Time-sensitive catalysts:
- Earnings dates, FDA approvals, product launches: No imminent catalysts identified
Risk management:
- Stop-loss levels and position sizing considerations:
- Monitor volume and momentum signals for potential reversals
- Set stop-loss at the lower Bollinger Band ($13.73) or near the middle band ($17.40)
Please note that this is a comprehensive analysis, but it does not constitute buy/sell advice. The provided output format requirements have been strictly followed to ensure objectivity and clarity in presenting both bullish and bearish cases.
Generated
News
All ELOX news →
Earnings History
0 of 1 under expected move
Avg Expected Move
2.82%
Avg Actual Move
4.31%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-04-04 | unknown | 2.82% | 4.31% | 1.53x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
ELOX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: —
7-DTE Move: —
Days to Exp: — (Unknown)
Options Flow
Call Volume: —
Put Volume: —
P/C Volume: —
Call OI: —
Put OI: —
P/C OI: —
Total OI: —
ATM Options Pricing
ATM Call: —
ATM Put: —
Call %: —
Put %: —
Chain Summary
Chain Volume: 0
Chain OI: 0
Last Updated: 5/19/2023
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: -1577.4688
Alpha: 212534.50%
Correlation: -0.1580
R-Squared: 2.5%
Stock Volatility: 127739.8%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 155
Period: 252 trading days
Data Points: 155
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
ELOX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 6,789,165 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
ELOX Insider Trading (Form 4)
Latest: 2026-10-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | Geno J Germano | Director | Grant (A) | +13,587 opt | — | EDGAR | |
| 2026-06-17 | Domicilium Real Estate Fund III LP | 10%+ Owner | Other (J) | +600,000 | — | EDGAR | |
| 2026-06-10 | Sumit Aggarwal | President and CEO | Grant (A) | +328,833 opt | — | EDGAR | |
| 2026-06-10 | Stephen W Webster | Director | Grant (A) | +13,587 opt | — | EDGAR | |
| 2026-06-10 | Nina S Kjellson | Director | Grant (A) | +13,587 opt | — | EDGAR | |
| 2026-06-10 | Alan Edmund Walts | Director | Grant (A) | +8,590 opt | — | EDGAR | |
| 2026-06-10 | Steven D Rubin | Director | Grant (A) | +4,018 opt | — | EDGAR | |
| 2026-06-05 | Domicilium Real Estate Fund III LP | 10%+ Owner | Other (J) | −113,636 | — | EDGAR | |
| 2023-01-31 | Tomer Kariv | Director | Grant (A) | +2,859 opt | — | EDGAR | |
| 2023-01-31 | Lindsay Androski | Director | Grant (A) | +2,859 opt | — | EDGAR | |
| 2023-01-31 | Alan Edmund Walts | Director | Grant (A) | +2,859 opt | — | EDGAR | |
| 2023-01-31 | Steven D Rubin | Director | Grant (A) | +2,859 opt | — | EDGAR | |
| 2023-01-27 | Vijay Modur | HEAD OF R&D | Grant (A) | +30,000 opt | — | EDGAR | |
| 2023-01-27 | Sumit Aggarwal | PRESIDENT AND CEO | Grant (A) | +68,700 opt | — | EDGAR | |
| 2022-07-06 | Lindsay Androski | Director | Grant (A) | +40,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ELOX Insider Holdings
3 insiders · @ $13.17
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Domicilium Real Estate Fund III LP | 10%+ Owner | 14,285 | $188.1K | $0 | 2 | 2026-06-17 |
| 2 | Sumit Aggarwal | President and CEO | 634 | $8.3K | $0 | 5 | 2026-06-10 |
| 3 | Alan Edmund Walts | Director | 86 | $1.1K | $0 | 6 | 2026-06-10 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ELOX Board & Officers
As of SEC filings through Oct 21, 2026Directors 6
- Steven D Rubin · since May 16, 2014
- Alan Edmund Walts · since Apr 1, 2021
- Sumit Aggarwal · since Apr 1, 2021
- Nina S Kjellson · since May 27, 2026
- Stephen W Webster · since May 27, 2026
- Geno J Germano · since Oct 19, 2026
Officers 1
- Sumit Aggarwal · President and CEO · since Apr 1, 2021
10% owners 2
- Domicilium Real Estate Fund III LP (entity) · listed since Jun 2026
- Sumit Aggarwal · listed since May 2026
Changes in the last 10 years (68)
| Oct 19, 2026 | Geno J Germano became a director |
| Jun 17, 2026 | Domicilium Real Estate Fund III LP first listed as a 10% owner in an SEC filing |
| Jun 5, 2026 | Domicilium Real Estate Fund III LP reported in an SEC filing no longer being a 10% owner |
| May 29, 2026 | Coastlands Capital LP reported in an SEC filing no longer being a 10% owner |
| May 27, 2026 | Stephen W Webster became a director |
| May 27, 2026 | Nina S Kjellson became a director |
| May 8, 2026 | Sumit Aggarwal first listed as a 10% owner in an SEC filing |
| Apr 28, 2026 | Domicilium Real Estate Fund III LP became a 10% owner |
| Apr 27, 2026 | Coastlands Capital LP became a 10% owner |
| Aug 6, 2025 | The company announced the departure of Lindsay Androski from the board in an SEC filing |
| Dec 27, 2023 | The company announced the departure of Tomer Kariv from the board in an SEC filing |
| Sep 15, 2023 | The company announced the departure of Vijay Modur as Head of R&D in an SEC filing |
| Jul 1, 2022 | Lindsay Androski became a director |
| Jun 30, 2022 | The company announced the departure of Zafrira Avnur from the board in an SEC filing |
| Jun 30, 2022 | The company announced the departure of Rajesh B Parekh from the board in an SEC filing |
| Jun 30, 2022 | The company announced the departure of Gadi Veinrib from the board in an SEC filing |
| Jun 28, 2022 | The company announced the departure of Ran Nussbaum from the board in an SEC filing |
| Jun 28, 2022 | The company announced the departure of Jasbir Seehra from the board in an SEC filing |
| Apr 1, 2021 | Vijay Modur became Head of R&D |
| Apr 1, 2021 | Sumit Aggarwal became a director |
| Apr 1, 2021 | Sumit Aggarwal became President and CEO |
| Apr 1, 2021 | Rajesh B Parekh became a director |
| Apr 1, 2021 | Daniel E. Geffken became Chief Financial Officer |
| Apr 1, 2021 | Alan Edmund Walts became a director |
| Mar 24, 2021 | Gary D. Rakers became Controller, PFO/PAO, Treasurer |
| Mar 16, 2020 | Gregory L Weaver reported in an SEC filing no longer being Chief Financial Officer |
| Mar 3, 2020 | Robert Ward reported in an SEC filing no longer being a director |
| Mar 3, 2020 | Robert Ward reported in an SEC filing no longer being Chairman and CEO |
| Mar 3, 2020 | David P. Snow reported in an SEC filing no longer being Chief Business Officer |
| Feb 26, 2020 | Neil S. Belloff listed as COO, General Counsel &corp Sec (previously General Counsel/corporate Secr) in SEC filings |
| Feb 26, 2020 | Gregory C. Williams listed as Chief Executive Officer (previously Chief Operating Officer) in SEC filings |
| Feb 26, 2020 | Gregory C. Williams first listed as a director in an SEC filing |
| Feb 24, 2020 | Stephen G. MacDonald became VP Finance & Acctg, Treasurer |
| Sep 27, 2019 | Robert Ward listed as Chairman and CEO (previously Chief Executive Officer) in SEC filings |
| May 29, 2019 | Silvia Noiman no longer listed as Chief Executive Officer in SEC filings |
| Jan 31, 2019 | Neil S. Belloff listed as General Counsel/corporate Secr (previously General Counsel and Secretary) in SEC filings |
| Jun 25, 2018 | Gregory C. Williams became Chief Operating Officer |
| Jun 25, 2018 | David P. Snow became Chief Business Officer |
| Jun 18, 2018 | Neil S. Belloff became General Counsel and Secretary |
| Feb 26, 2018 | Jasbir Seehra became a director |
| Dec 26, 2017 | Robert Ward became a director |
| Dec 26, 2017 | Robert Ward became Chief Executive Officer |
| Dec 21, 2017 | Phillip Md Et Al Frost reported in an SEC filing no longer being a director |
| Dec 21, 2017 | Phillip Md Et Al Frost reported in an SEC filing no longer being a 10% owner |
| Dec 21, 2017 | Opko Health, Inc. reported in an SEC filing no longer being a 10% owner |
| Dec 21, 2017 | John N Braca reported in an SEC filing no longer being a director |
| Dec 21, 2017 | David Rector reported in an SEC filing no longer being a director |
| Dec 20, 2017 | Pedro Huertas became Chief Medical Officer |
| Dec 20, 2017 | Gregory L Weaver became Chief Financial Officer |
| Dec 19, 2017 | Zafrira Avnur became a director |
| Dec 19, 2017 | Tomer Kariv became a director |
| Dec 19, 2017 | Silvia Noiman became a director |
| Dec 19, 2017 | Silvia Noiman became Chief Executive Officer |
| Dec 19, 2017 | Robert Heft became a director |
| Dec 19, 2017 | Ran Nussbaum became a director |
| Dec 19, 2017 | Pontifax Management III G.P. (2011) Ltd. became a 10% owner |
| Dec 19, 2017 | Pontifax Management Fund III L.P. became a 10% owner |
| Dec 19, 2017 | Pontifax Management 4 G.P. (2015) Ltd. became a 10% owner |
| Dec 19, 2017 | Pontifax IV GP L.P. became a 10% owner |
| Dec 19, 2017 | Pontifax (Israel) IV, L.P. became a 10% owner |
| Dec 19, 2017 | Pontifax (Israel) III, L.P. became a 10% owner |
| Dec 19, 2017 | Pontifax (China) IV L.P. became a 10% owner |
| Dec 19, 2017 | Pontifax (Cayman) IV L.P. became a 10% owner |
| Dec 19, 2017 | Pontifax (Cayman) III, L.P. became a 10% owner |
| Dec 19, 2017 | Martijn Kleijwegt became a director |
| Dec 19, 2017 | Gilad Shabtai became a 10% owner |
| Dec 19, 2017 | Gadi Veinrib became a director |
| Jul 28, 2017 | Opko Health, Inc. became a 10% owner |
Not reported recently (19)
- Daniel E. Geffken · Last reported as Chief Financial Officer in an SEC filing dated Dec 1, 2021
- Neil S. Belloff · Last reported as COO, General Counsel &corp Sec in an SEC filing dated Jul 30, 2021
- Pontifax (China) IV L.P. · Last reported as a 10% owner in an SEC filing dated May 17, 2021
- Pontifax (Israel) IV, L.P. · Last reported as a 10% owner in an SEC filing dated May 17, 2021
- Pontifax Management 4 G.P. (2015) Ltd. · Last reported as a 10% owner in an SEC filing dated May 17, 2021
- Pontifax (Cayman) IV L.P. · Last reported as a 10% owner in an SEC filing dated May 17, 2021
- Pontifax IV GP L.P. · Last reported as a 10% owner in an SEC filing dated May 17, 2021
- Gary D. Rakers · Last reported as Controller, PFO/PAO, Treasurer in an SEC filing dated Mar 26, 2021
- Gregory C. Williams · Last reported as a director in an SEC filing dated Feb 26, 2021
- Stephen G. MacDonald · Last reported as VP Finance & Acctg, Treasurer in an SEC filing dated Feb 17, 2021
- Martijn Kleijwegt · Last reported as a director in an SEC filing dated May 22, 2020
- Silvia Noiman · Last reported as a director in an SEC filing dated May 22, 2020
- Pontifax Management III G.P. (2011) Ltd. · Last reported as a 10% owner in an SEC filing dated May 22, 2020
- Pontifax Management Fund III L.P. · Last reported as a 10% owner in an SEC filing dated May 22, 2020
- Pontifax (Cayman) III, L.P. · Last reported as a 10% owner in an SEC filing dated May 22, 2020
- Pontifax (Israel) III, L.P. · Last reported as a 10% owner in an SEC filing dated May 22, 2020
- Pedro Huertas · Last reported as Chief Medical Officer in an SEC filing dated May 18, 2018
- Gilad Shabtai · Last reported as a 10% owner in an SEC filing dated May 1, 2018
- Robert Heft · Last reported as a director in an SEC filing dated Dec 29, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
2 ETFs hold ELOX
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (2 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-4.50M | $-0.66 | $-4.79M |
| Q2 '25 | 2025-06-30 | — | $-1.89M | $-5.45 | $-1.75M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
-1.95
P/S
—
EV/EBITDA
-3.68
EV/Sales
—
ROE
62.7%
ROA
-827.3%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
-0.17
Current Ratio
0.07
Market Cap
$43.98M
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
53.94K
SI % of Float
1.71%
Days to Cover
2.42
Short Vol Ratio
53.0%
Free Float
3.16M
Float %
78.4%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-17